![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. (+-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic Acid
2. Dostein
3. Edirel
4. Esteclin
5. Rv 144
6. Rv-144
7. S-(2-(n-3-(2-oxo-tetrahydrothienyl)acetamido))thioglycolic Acid
8. Vectrine
1. 84611-23-4
2. Rv 144
3. Erdosteine [inn]
4. Mucotec
5. 105426-14-0
6. Rv-144
7. 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic Acid
8. 2-((2-oxo-2-((2-oxotetrahydrothiophen-3-yl)amino)ethyl)thio)acetic Acid
9. 76j0853eka
10. Erdosteine (inn)
11. Kw-9144
12. Ncgc00185774-01
13. 2-({[(2-oxothiolan-3-yl)carbamoyl]methyl}sulfanyl)acetic Acid
14. Acetic Acid, [[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]-
15. Dsstox_cid_28661
16. Dsstox_rid_82931
17. Dsstox_gsid_48735
18. Erdosteinum [latin]
19. Dithiosteine
20. Erdosteinum
21. Vectrine
22. Edirel
23. ({2-oxo-2-[(2-oxotetrahydro-3-thienyl)amino]ethyl}sulfanyl)acetic Acid
24. Acetic Acid, ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)-
25. Cas-84611-23-4
26. Secresolv
27. Erdosteine [inn:ban]
28. Pv 144
29. Erdostiene
30. Erdotin
31. Unii-76j0853eka
32. 2-(2-oxo-2-(2-oxotetrahydrothiophen-3-ylamino)ethylthio)acetic Acid
33. Erdosteine,(s)
34. Mucotec (tn)
35. Erdosteine [mi]
36. Dl-s-(2-(n-3-(2-oxotetrahydrotheinyl)acetamido))thioglycolic Acid
37. ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)acetic Acid
38. (+-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic Acid
39. Acide ((2-oxo-3-tetrahydrothienylcarbamoyl)-methylthio)acetique [french]
40. Erdosteine [mart.]
41. Erdosteine [who-dd]
42. Schembl21721
43. Mls006010056
44. Chembl1697744
45. Dtxsid8048735
46. Erdosteine, >=98% (hplc)
47. Chebi:135014
48. Hms3264c11
49. Hms3655i14
50. Acide ((2-oxo-3-tetrahydrothienylcarbamoyl)-methylthio)acetique
51. Hy-b0289
52. Tox21_113176
53. Mfcd00867664
54. S1825
55. Stl452949
56. Akos015888361
57. Tox21_113176_1
58. Ac-5278
59. Ccg-213836
60. Db05057
61. Ks-1352
62. Ncgc00185774-02
63. Ncgc00185774-09
64. Smr002529560
65. E1026
66. Ft-0625684
67. Ft-0630929
68. Sw220302-1
69. D07383
70. T72990
71. Ab01274804-01
72. Ab01274804_02
73. Ab01274804_03
74. 611e234
75. A840878
76. Sr-01000944253
77. Q3731252
78. Sr-01000944253-1
79. N-(tetrahydro-2-oxo-3-thienyl)-3-thiapentanedioic Acid Monoamide
80. ({2-oxo-2-[(2-oxotetrahydrothiophen-3-yl)amino]ethyl}sulfanyl)acetic Acid
81. (+/-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic Acid
82. 2-[2-oxo-2-[(2-oxotetrahydrothiophen-3-yl)amino]ethyl]sulfanylacetic Acid;erdosteine
83. Erdosteine; [[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]acetic Acid
Molecular Weight | 249.3 g/mol |
---|---|
Molecular Formula | C8H11NO4S2 |
XLogP3 | -0.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 249.01295018 g/mol |
Monoisotopic Mass | 249.01295018 g/mol |
Topological Polar Surface Area | 134 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 282 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Fro the treatment of chronic bronchitis in adults.
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
R05CB15
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R05 - Cough and cold preparations
R05C - Expectorants, excl. combinations with cough suppressants
R05CB - Mucolytics
R05CB15 - Erdosteine
Erdosteine, is an orally administered mucolytic agent. It is classified as a thiol derivative and produced for the management of symptoms caused by chronic obstructive bronchitis. Erdosteine contains sulfhydryl groups which are released after hepatic first-pass metabolism in the liver. Its active metabolites (3 in number) exert both mucolytic activity and scavenging activity against free radicals. Erdosteine acts to regulate the production of mucus in the airway and regulates its viscosity while enhancing mucociliary transport. This leads to an increase in expectoration. Erdosteine shows inhibition against the effects of free radicals from cigarette smoke. Clinical studies in patients with chronic obstructive lung disease (COPD) have shown that this drug is generally safe and well tolerated. Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.